Diabetes: cross-border specialty drug access for international patients

Endocrinology and metabolic disease

ICD-10: E10-E14

Quick orientation

An estimated 537 million adults globally have diabetes (IDF 2021). Type 2 diabetes accounts for over 90 percent of cases; type 1 affects approximately 8.4 million people worldwide.

Typical age of onset. Type 1 diabetes typically presents in childhood or adolescence; type 2 in adulthood though increasingly in younger ages.

Severity tiers. Severity ranges from well-controlled mild disease to insulin-dependent forms with high complication risk. Long-term complications include cardiovascular disease, retinopathy, nephropathy, and neuropathy.

Why specialty drugs for Diabetes are hard to access internationally

Standard diabetes drugs are broadly available, but several newer GLP-1 receptor agonists, dual incretin agents, and ultra-long-acting insulins have intermittent supply outside the US and EU. Demand-driven shortages in 2024 and 2025 made these particularly hard to source through normal channels in MENA, South Asia, and Latin America.

Treatments approved by the FDA

Ozempic (semaglutide) — FDA approval: 2017. Mechanism: GLP-1 receptor agonist. Route: Subcutaneous injection weekly. US WAC ballpark: Approximately USD 900 to 1,200 per month. Country pricing: UAE · Saudi Arabia · India · Egypt.
Mounjaro (tirzepatide) — FDA approval: 2022. Mechanism: Dual GIP and GLP-1 receptor agonist. Route: Subcutaneous injection weekly. US WAC ballpark: Approximately USD 1,000 to 1,300 per month. Country pricing: UAE · Saudi Arabia · India · Egypt.
Wegovy (semaglutide) — FDA approval: 2021. Mechanism: GLP-1 receptor agonist (obesity indication, often used in diabetes-related obesity). Route: Subcutaneous injection weekly. US WAC ballpark: Approximately USD 1,300 per month. Country pricing: UAE · Saudi Arabia · India · Egypt.
Awiqli (insulin icodec) — FDA approval: 2024. Mechanism: Once-weekly basal insulin analog. Route: Subcutaneous injection weekly. US WAC ballpark: Approximately USD 350 per month. Country pricing: Egypt · Jordan · Oman.

Cross-border pathways used for Diabetes

Most patients use one or more of the following regulatory pathways, depending on the destination country and the specific drug:

What your physician needs to know

Confirm type of diabetes and current regimen.
Document HbA1c, fasting glucose, and any complication-related labs.
GLP-1 agonists carry risks of pancreatitis, gallbladder events, and gastrointestinal effects; screen accordingly.
For weekly basal insulin, counsel on hypoglycemia risk and timing of meals.
Endocrinologist co-management is recommended for complex or insulin-dependent regimens.

Common questions

Are GLP-1 drugs available locally?

Availability varies and supply has been intermittent globally. We confirm current status by destination.

Can I switch between Ozempic, Mounjaro, and others?

Switching is feasible and sometimes indicated. Your endocrinologist guides the transition.

Is Awiqli approved in my country?

Once-weekly insulin icodec is approved in the EU, Canada, and several other markets. Status in MENA and South Asia varies.

What documents are required?

Endocrinologist's prescription, recent HbA1c, and any prior regimen history.

How fast does Reserve Meds ship?

Five to ten business days from prescription receipt for most diabetes specialty drugs.

Where Reserve Meds fits in

Reserve Meds is a cross-border specialty drug access platform. We support international patients whose prescribed FDA-approved medicine is not registered locally, is not reimbursed by their payer, or is otherwise unavailable through standard channels. For Diabetes, our role is to coordinate the regulatory pathway, source the medicine from a DSCSA-compliant US wholesaler, and arrange validated cold-chain or controlled-temperature shipment to the destination country.

We do not replace your treating physician. We do not bill insurance. We operate a cash-pay model, and we work alongside the clinical team that knows your case. Every prescription is reviewed by a US-licensed pharmacist before dispense, and a US-licensed physician reviews the supply request before shipment.

Start a request

Request a drug for Diabetes

Reserved for you.